ICOS is a Robust T-cell Activation Marker and a Prognostic Biomarker in HNSCC
NSCLC, tumor, melanoma, cancer, HNSCC, lung carcinoma, TCGA, HNSCC
CANCER, TUMOR, MELANOMA, NSCLC
Primary PBMC-derived T cells were stimulated with plate-bound anti-CD3/CD28 to evaluate the kinetics of ICOS expression following T-cell activation. Consistent with the transient nature of ICOS expression, and dependence on TCR activation (As some level of T-cell activation may be expected in or around the tumor microenvironment (TME), we also evaluated ICOS mRNA expression in a range of cancer settings using TCGA database. We found that ICOS gene expression was enriched in several tumor indications, including HNSCC, lung carcinoma, melanoma, and bladder cancer (To corroborate the publicly available TCGA data and evaluate cell-specific ICOS expression, we analyzed available melanoma, HNSCC, and NSCLC single-cell RNA-seq datasets (